JP2020533296A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533296A5
JP2020533296A5 JP2020513603A JP2020513603A JP2020533296A5 JP 2020533296 A5 JP2020533296 A5 JP 2020533296A5 JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020533296 A5 JP2020533296 A5 JP 2020533296A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
predopidine
levodopa
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533296A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048920 external-priority patent/WO2019050775A1/en
Publication of JP2020533296A publication Critical patent/JP2020533296A/ja
Publication of JP2020533296A5 publication Critical patent/JP2020533296A5/ja
Pending legal-status Critical Current

Links

JP2020513603A 2017-09-08 2018-08-30 薬物誘発性ジスキネジアを治療するためのプリドピジン Pending JP2020533296A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762556314P 2017-09-08 2017-09-08
US62/556,314 2017-09-08
US201862649184P 2018-03-28 2018-03-28
US62/649,184 2018-03-28
PCT/US2018/048920 WO2019050775A1 (en) 2017-09-08 2018-08-30 PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
JP2020533296A JP2020533296A (ja) 2020-11-19
JP2020533296A5 true JP2020533296A5 (OSRAM) 2021-03-04

Family

ID=63684481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513603A Pending JP2020533296A (ja) 2017-09-08 2018-08-30 薬物誘発性ジスキネジアを治療するためのプリドピジン

Country Status (10)

Country Link
US (2) US20190231768A1 (OSRAM)
EP (1) EP3678664A1 (OSRAM)
JP (1) JP2020533296A (OSRAM)
CN (1) CN111343982A (OSRAM)
AU (1) AU2018329628B2 (OSRAM)
BR (1) BR112020004622A2 (OSRAM)
CA (1) CA3075020C (OSRAM)
IL (1) IL273044A (OSRAM)
MX (1) MX383462B (OSRAM)
WO (1) WO2019050775A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011298382A1 (en) 2010-09-03 2013-05-02 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
KR20250021199A (ko) 2023-08-03 2025-02-12 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
DK2146961T3 (da) 2007-04-12 2014-04-28 Ivax Int Gmbh N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler
WO2008155357A2 (en) * 2007-06-18 2008-12-24 A. Carlsson Research Ab Use of dopamine stabilizers
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
AU2011298382A1 (en) 2010-09-03 2013-05-02 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
KR20140075703A (ko) * 2011-09-07 2014-06-19 아이백스 인터내셔널 게엠베하 프리도피딘 하이드로클로라이드의 다형 형태
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 併用療法のための医薬組成物
KR102316933B1 (ko) 2013-06-21 2021-10-26 프리레니아 뉴로테라퓨틱스 엘티디. 헌팅턴병 치료를 위한 프리도피딘의 용도
DK177976B8 (en) 2013-07-10 2021-04-22 Jasopels As Apparatus and method for stretching a pelt on a pelt board
DK3096759T3 (da) 2014-01-22 2022-05-09 Prilenia Neurotherapeutics Ltd Pridopidinformuleringer med modificeret frigivelse
KR102166879B1 (ko) 2014-03-10 2020-10-16 어플라이드 머티어리얼스, 인코포레이티드 다중 하전-입자 빔 리소그래피를 위한 픽셀 블렌딩
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのl−酒石酸塩
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
AU2017223838B2 (en) 2016-02-24 2022-09-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
US20200375966A1 (en) 2016-09-15 2020-12-03 Prilenia Therapeutics Development Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
HUE068300T2 (hu) 2017-01-20 2024-12-28 Prilenia Neurotherapeutics Ltd Pridopidin törékeny X szindróma kezelésében történõ alkalmazásra
BR112020003119A2 (pt) 2017-08-14 2020-10-13 Prilenia Neurotherapeutics Ltd. método de tratamento de esclerose lateral amiotrófica com pridopidina
JP2020532517A (ja) * 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
DE102018204527A1 (de) 2017-09-18 2019-03-21 SEs Solutions GmbH Dachhalterung für ein Automobil

Similar Documents

Publication Publication Date Title
JP2020533296A5 (OSRAM)
FI2629097T1 (fi) Nrf2-seulontatestejä ja niihin liittyviä menetelmiä ja koostumuksia
JP2010518122A5 (OSRAM)
JP2019503365A5 (OSRAM)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
JP2013529665A5 (OSRAM)
JP2019515884A5 (OSRAM)
JP2018527305A5 (OSRAM)
JP2018500300A (ja) パーキンソン病を遅延させるための医薬
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
JP2005528430A5 (OSRAM)
JP2019218379A5 (OSRAM)
JP2020522560A5 (OSRAM)
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2016505050A5 (OSRAM)
EP2968227B1 (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
JP2020509072A5 (OSRAM)
JP2016528171A5 (OSRAM)
JP2019507786A5 (OSRAM)
JP2020531543A5 (OSRAM)
WO2016073716A1 (en) Methods of treating huntington's disease using cysteamine compositions
JP2019085364A5 (OSRAM)